Corticotrophin-releasing factor-like immunoreactivity and bioactivity of human fetal and adult hypothalami
- 1 February 1986
- journal article
- research article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 108 (2) , 171-180
- https://doi.org/10.1677/joe.0.1080171
Abstract
Corticotrophin releasing factor-like immunoreactivity (CRF-LI) and bioactivity, and arginine vasopressinlike immunoreactivity (AVP-LI) have been measured in extracts of human fetal and adult hypothalamic tissue and their development with the gestational age of the fetuses (12–27 weeks) studied. CRF-LI was measured by a radioimmunoassay developed for ovine corticotrophin-releasing factor (oCRF-41). Corticotrophin-releasing factor bioactivity was measured in a rat isolated anterior pituitary cell perfusion system. CRF-LI and bioactivity and AVP-LI were all detectable in fetal hypothalamic extracts from 12 to 13 weeks of gestational age. CRF-LI was also present in human fetal pituitary glands from 12 weeks of gestational age. The concentration of CRF-LI in the fetal hypothalamic extracts (9·2±11·4 ng/g, mean ± s.e.m., n = 33) showed no significant correlation with the gestational age of the fetuses. However the concentration of AVP-LI (25·0–36·8 ng/g, n = 17) did show a positive correlation (r = 0·508, Pn = 13, r = 0·725, P < 0·01). The CRF bioactivity of all fetal hypothalamic extracts was potentiated by the addition of synthetic human (h)AVP, but the bioactivity of the adult hypothalamic extracts was not, presumably because of the higher levels of AVP-LI already present in the adult extracts. Pretreatment of tissue extracts with antisera to oCRF-41 and/or hAVP reduced the CRF bioactivity of all hypothalamic extracts. Sephadex chromatography of fractions which co-eluted with synthetic oCRF-41 or hAVP contained CRF bioactivity and this bioactivity was potentiated when synthetic hAVP or oCRF-41, respectively, were added to the fractions. However, a larger molecular weight form of CRF-LI (8000–10 000 daltons), which was observed only in fetuses of 20 weeks of gestational age or less, did not contain any significant CRF bioactivity. J. Endocr. (1986) 108, 171–180This publication has 20 references indexed in Scilit:
- NEW HYPOTHALAMIC HORMONE, CORTICOTROPIN-RELEASING FACTOR, SPECIFICALLY STIMULATES THE RELEASE OF ADRENOCORTICOTROPIC HORMONE AND CORTISOL IN MANThe Lancet, 1982
- In Vivo Corticotropin-Releasing Factor-Induced Secretion of Adrenocorticotropin, β-Endorphin, and Corticosterone*Endocrinology, 1982
- Primary structure of corticotropin-releasing factor from ovine hypothalamus.Proceedings of the National Academy of Sciences, 1981
- Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-EndorphinScience, 1981
- Ontogenesis of Gonadotropin-Releasing Hormone in the Human Fetal HypothalamusExperimental Biology and Medicine, 1980
- Characterization of Rat Stalk Median Eminence Vasopressin and Its Involvement in Adrenocorticotropin ReleaseEndocrinology, 1978
- Perfused Rat Isolated Anterior Pituitary Cell Column as Bioassay for Factor(s) Controlling Release of Adrenocorticotropin: Validation of a TechniqueEndocrinology, 1978
- The Ontogenesis of Human Fetal Hormones. IV. Somatostatin, Luteinizing Hormone Releasing Factor, and Thyrotropin Releasing Factor in Hypothalamus and Cerebral Cortex of Human Fetuses 10-22 Weeks of AgeJournal of Clinical Endocrinology & Metabolism, 1977
- PROLACTIN RELEASING ACTIVITY IN THE EARLY HUMAN FOETAL HYPOTHALAMUSJournal of Endocrinology, 1977
- The Status of the Corticotropin Releasing Factor (CRF)Neuroendocrinology, 1977